Statistics from Altmetric.com
Randomised, double blind, placebo controlled trial with 12 weeks follow up.
7 trial centres in Latvia.
167 care dependent inpatients with moderately severe to severe dementia defined by DSM-III-R criteria (49% Alzheimer's disease, 51% vascular dementia) and with severity assessed by the Global Deterioration Scale (stages 5–7) and the Mini-Mental State Examination (<10 points). Exclusion criteria included duration of dementia <12 months; central nervous system active drugs within the previous 14 days; severe, chronic, or terminal diseases; impaired thyroid function, lowered B12 blood concentration; abnormal blood chemistry; alcoholism or drug addiction; major depression; learning disability; epilepsy; and Parkinson's disease. 1 patient was excluded from the analysis.
82 patients were assigned to memantine (5 mg/d during the first week and 10 mg/d during the next 11 wks) and 84 to placebo.
Main outcome measures
Clinical Global Impression of Change (CGI-C) rated by the physician, and the Behavioural Rating Scale for Geriatric Patients (BGP), subscore “care dependence,” rated by the nursing staff.
At 12 …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.